• SELECT SITE CURRENCY
Select a currency for use throughout the site
NICE Guidelines on Peginterferon Alfa and Ribavirin for the Treatment of Mild Chronic Hepatitis C
Just Medical Media, March 2007, Pages: 8
Chronic HCV infection is common in the UK with estimates suggesting that up to 500,000 people carry this virus. Infection is common in those who use illicit drugs (either injected or inhaled drugs such as heroin or cocaine), though HCV is also found at high frequency in those who have received healthcare in underdeveloped parts of the world.
This title provides a specialist’s perspective of the new NICE guidelines and provides a summary of the NICE guidelines for the treatment of mild chronic hepatitis C. It looks at what the new guidelines will add and provides recommendations for their implementation.
Commentary: A specialist’s perspective of the new NICE guidelines
Treatment of mild chronic hepatitis C: A summary of the NICE guidelines
- What do the new guidelines add?
- Guideline recommendations
- Early treatment or watchful waiting?
- Haematological tests and biopsies
- Genotype, viral load, drug dose and duration of treatment
- Treatment in patients with normal transaminase levels
Current management of hepatitis C in primary care and the likely impact of the new NICE guidance
- Primary care welcomes new NICE guidance
- Poor state of hepatitis C in primary care and PCTs
- Improving practice in primary care
- Structured multidisciplinary working
- Key points
A sample for this product is available. Please Login/Register to download this sample.